香港, 2026年3月27日 - (亞太商訊) - 3月27日，美麗田園醫療健康（02373.HK）正式發佈2025年度業績報告。年內，集團營收、利潤、現金流全方位高質量增長，以硬核業績凸顯行業龍頭的強增長韌性。集團盈利能力實現跨越式躍升。2025年，美麗田園集團總收入30億元，同比增長16.7%；毛利率提升至49.1%，同比提高2.8個百分點；經調淨利潤攀升至3.8億元，同比大幅增長41.0%，經調整淨利率達12.7%，提高2.2個百分點，盈利水平邁上新台階。公司持續顯現「現金牛屬性」。2025年集團經營活動產生的現金流量淨額達10.0億元，同比大幅增長25.4%；截至2025年12月31日，集團現金及類現金項目金額合計高達25.9億元，同比淨增41.6%，充沛且強勁的現金流為集團戰略投資與股東回報提供充足動能。這份營收與利潤大幅增長的亮眼業績，是集團「內生增長+外延並購」商業模式的成功體現，也是集團精益管理、提質增效及數智化賦能帶動整體效率提升的有力印證。「雙美+雙保健」模式賦能，盈利能力全面上揚作為核心基石業務，集團美與健康板塊逆勢高增，全年交出令市場矚目的亮眼答卷。2025年，美容和保健服務收入16.6億元，同比增長14.9%；毛利率提升1.2個百分點至41.9%；直營門店客流達172.4萬人次，同比增長23.2%；直營活躍會員增至14.6萬名，同比增長11.8%，直營活躍會員年均消費金額9738元，同比提升320元。直營活躍會員規模與年均消費實現雙增長。業績高質量增長的同時，集團錨定長期發展戰略。2025年，我們正式發佈超級供應鏈戰略，全面升級產品創研體系。未來，產品創研方式將全新拓展為全球精選、國際品牌合作、國際頂尖實驗室聯合研發三大模式並進，在傳承卓越品質的同時，注入創新動能。2026年2月，我們重磅宣佈與全球知名護膚品牌資生堂達成重磅戰略合作，在品牌影響力、服務體驗、科研共創等多維度深度攜手，開啟美與健康領域合作的新篇章。消費醫療兼具醫療價值屬性與消費彈性，是承載長期結構性機遇的優質賽道。美麗田園集團深耕消費醫療賽道，圍繞高端女性美與健康的核心醫療需求深度延伸佈局。過去16年，我們從0到1自建消費醫療能力，目前全國落地38家消費醫療機構，形成規模化佈局。2025年，消費醫療板塊整體收入13.4億，同比增長18.9%，占收入比例達到44.8%，成為重要的增長驅動力。具體來看，2025年集團醫療美容服務-秀可兒醫美逆勢增長，實現收入10.2億元，同比增長9.6%，毛利率大幅提升3.6個百分點至55.9%；客流10.2萬人次，同比增長13.1%，活躍會員攀升至3.6萬名，同比增長7.7%；活躍會員年均消費27,862元，同比增加490元。為進一步破局行業競爭、打造差異化核心優勢，秀可兒醫美精准錨定「專研抗衰」賽道，以「專家、專研、專注原生美」為品牌定位。2026年3月，Cellcare秀可兒品牌舉辦「專研抗衰」品牌升級發佈會，圍繞不同年齡層女性抗衰需求，打造 「初老抗衰、凍齡抗衰、逆齡抗衰」 的全週期產品藍圖，正式開啟秀可兒專研抗衰新時代。亞健康醫療服務--研源醫療作為集團增值業務迎來爆發式增長。2025年，研源醫療收入3.3億元，同比大增62.2%，收入佔比首次突破10%，成為集團業績增長的重要引擎；毛利率升至64.3%，同比提升6.1個百分點；客流量3.7萬人次，同比增長35.7%，活躍會員人數同比大增37.9%，活躍會員年平均消費28,032元，同比增加6287元。2025年，研源醫療旗下功能醫學板塊收入同比增長101%。在AI浪潮之下，我們將通過自研AI模型，深度融合精准檢測數據、專家診療路徑與臨床案例，實現「千人千面」的個性化診療方案與7x24全天候服務，以科技賦能醫療服務全面升級。研源醫療旗下女性特護板塊收入增長64%。我們將持續拓展服務版圖，構建「預防-治療-抗衰」女性健康醫療服務。並購整合戰略升級，以共贏之姿賦能行業發展中國「美與健康」市場坐擁萬億賽道規模，機遇與挑戰並存，合作共贏已經成為行業發展的必然趨勢。美麗田園主動投身行業整合進程，將投資並購上升為集團級核心戰略，以開放共贏的姿態攜手行業夥伴，共同推動美業高質量發展。2026年3月，集團重磅舉辦「尋找100位美業同行者」戰略投資暨行業賦能發佈會，宣佈將聚焦中國20個高線城市的美與健康服務機構，誠邀更多行業夥伴融入美麗田園生態體系，依託持續打磨精進的商業系統為行業夥伴提供全方位賦能提效，實現共生共贏。這一戰略佈局的底氣，源自集團過往逾30多起收並購項目中所積澱的深厚實戰經驗與可複製的整合方法論。2024年，集團完成對中國美容行業市占率第二大品牌奈瑞兒的收購，並通過系統化、精細化整合，實現奈瑞兒收入和利潤雙提升。2025年，奈瑞兒單店收入從收購前的575萬提升至810萬、經調淨利率從6.5%大幅提升至10.5%，以亮眼的數據印證了美麗田園強大的並購整合能力，更形成了一套可複製、可延展的行業整合成功範式。2025年10月，美麗田園集團宣佈以12.5億元人民幣全資收購行業第三大品牌思妍麗100%股權。伴隨著思妍麗於2026年1月正式併入集團報表，我們將複製奈瑞兒成功經驗，充分發揮自身模式優勢和平台能力，為業績增長注入新動能。至此，三大品牌齊聚美麗田園集團麾下，市場佔有率實現跨越式提升，中國美容行業競爭格局重塑。重磅打造商業系統，構建企業可持續增長核心壁壘33 年深耕，美麗田園集團從美容服務逐步延伸至消費醫療，已成功建成面向高線城市女性的美與健康綜合服務平台。2025年，集團重磅打造美麗田園商業系統，從多維度構建企業可持續增長模式，為長遠發展築牢體系根基。客戶價值成長系統。通過精細化客戶運營體系，我們構建起覆蓋推廣、獲客、轉化、會員留存、價值提升、複購、裂變的全鏈路運營閉環，為客戶持續創造長期價值。強平台+多品牌系統。我們構建了「強平台+多品牌事業部」協同的組織體系，支撐多品牌、多業務高效聯動與協同發展。前台事業部聚焦市場與客戶，靈活作戰、快速響應；平台沉澱能力、輸出標準，讓協同貫穿業務全流程，有效提升運營效率與業務延展性，為多品牌有序擴張提供堅實組織支撐。並購價值成長系統。我們構建了「投資+整合+成長」全週期並購價值成長體系，通過持續積累行業獨特的投資數據、成熟的投前模型、精進的投中整合，全面提升投後價值，形成成熟的並購與賦能機制，可適配不同規模、不同業務的優質標的，真正實現「並購即融合、融合即增值」。數智化與AI系統。集團將構建數智化驅動的管理體系，深度賦能美麗田園商業系統，讓體系能力可落地、可複製、可迭代，成為集團穿越經濟週期、持續引領行業發展的堅實支柱。資本市場價值提升，持續釋放長期投資價值2025年3月，集團正式發佈三大舉措，圍繞股東結構優化、高分紅比例及管理層激勵，持續向資本市場釋放長期投資價值。股東結構優化方面，2025 年 8 月，原PE股東中信產業基金正式退出主要股東行列，同步引入優質長期戰略投資者，股東結構進一步夯實。分紅方面，2026年董事會提議延續高分紅比例，將2025年歸母淨利潤的50%用於分紅，派發每股0.72港元，同比增長38.5%，以真金白銀的回報持續強化股東回報，彰顯企業對自身發展的堅定信心。管理層激勵方面，2025年，集團將未來三年收入及利潤目標與股權激勵深度綁定，首年業績目標已超額達成，激勵機制的有效性得到充分驗證。在此基礎上，公司進一步上調管理層股權激勵對應的三年業績目標，以更高標準統一公司與股東利益，在釋放增長潛力的同時，為投資者創造長期穩定回報。2025 年 11 月，公司成功納入 MSCI 全球小型股指數，進一步進入全球被動及主動型基金視野，吸引更廣泛的國際投資者關注。未來展望：三大超級戰略領航，錨定長期高質量發展美麗田園集團的長期願景是成為中國美與健康的領航者。站在行業整合與品牌升級的新起點，2025年11月，美麗田園正式發佈超級品牌、超級連鎖、超級數字化三大戰略，為未來高質量發展指明方向，擘畫長期發展藍圖。超級品牌，構建美與健康品牌矩陣。我們持續升級專業實力，打造超越客戶期待的體驗，重塑美容行業價值新空間。同時，積極參與並推動行業標準制定，將美麗田園的高標準上升為行業共識，提升消費者信任與品牌價值。超級連鎖，我們將發揮「雙美+雙保健」商業模式優勢，通過內生增長與外延並購雙輪驅動戰略帶動公司價值躍升。我們致力於打造20個收入過億的核心城市，同時構建自有供應鏈能力，融合全球精選與聯合專研，為中國高線城市女性提供兼具專業性、個性化、高品質的美容和消費醫療產品與服務。超級數字化，我們致力於打造數智化與AI系統基礎建設，構建數智化驅動的企業管理體系，打造數智引領的美與健康服務連鎖標杆企業。結語未來，美麗田園將繼續堅守「以客戶為中心」的初心，依託「美麗田園商業系統」，以「三大超級戰略」為指引，在不斷滿足高線城市女性對美與健康的多元需求的同時實現立體增長，推動中國美與健康行業的高質量發展。 Copyright 2026 亞太商訊. All rights reserved. www.acnnewswire.com

RESULTS HIGHLIGHTS:- The Revenue for the year ended 31 December 2025 was approximately HK$3,736.5 million, representing an increase of approximately 11.1% as compared with the same period last year.- The Gross Profit Margin for the year ended 31 December 2025 was approximately 55.8%; the gross profit was approximately HK$2,085.0 million, representing an increase of approximately 15.9% as compared with the same period last year.- The Group’s EBITDA for the year ended 31 December 2025 was approximately HK$938.1 million, representing an increase of approximately 32.4% as compared with the same period last year.- The Group’s net profit for the year ended 31 December 2025 was approximately HK$601.2 million, representing an increase of approximately 47.7% as compared with the same period last year.- Basic earnings per share for the year ended 31 December 2025 amounted to approximately HK63.7 cents, representing an increase of approximately 47.5% as compared with the same period last year.- The Board recommended the payment of a final dividend of HK15.0 cents per ordinary share for the year ended 31 December 2025.- For the year ended 31 December 2025, the Group recorded approximately 1,039,000 cases digital solution cases produced from the Group’s production facilities in Mainland China, Thailand and Vietnam, reflecting an increase of 32.7% as compared with the same period in 2024 as a result of our clients’ continued adoption of intra-oral scanners.HONG KONG, Mar 27, 2026 - (ACN Newswire) - 26 March 2026, Modern Dental Group Limited (“Modern Dental” or “the Group”, stock code: 03600.HK), a leading global dental prosthetic device provider, announces its annual results for the year ended 31 December 2025 (“the year”).During the year ended 31 December 2025, the Group’s multi-dimensional strategies and continuous enhancement of operational efficiency and productivity as supported by the ongoing trend of digitalization in the dental industry have resulted in the Group reporting record revenues, net profit and EBITDA numbers during this period. This occurred in a period of challenging macro-economic environment with general softness in demand for dental procedures and trade war uncertainties. The Group has been proactive in its approach to deal with the unprecedented international trade environment leveraging its international production facilities located in Thailand, Vietnam and Mainland China.The global digitalization trend continues to drive consolidation within the dental prosthetics industry, enabling the Group to further expand its market share. Our ongoing digital transformation initiatives are enhancing both customer and patient experiences while improving operational efficiency, further differentiating the Group from competitors and positioning us to outperform industry peers. The Group’s underlying fundamentals remain solid, and we are well positioned to capitalize on emerging opportunities going forward.European BusinessesDuring the year ended 31 December 2025, the European market recorded a revenue of approximately HK$1,887.0 million, representing an increase of approximately HK$268.0 million as compared with the year ended 31 December 2024. This geographic market accounted for 50.5% of the Group’s total revenue. The increase of revenue from the European market was mainly attributable to the increase in sales order volume driven by the launch of new products, such as digital dentures, and our state-of-the-art digital workflows.The Group has been the frontrunner to provide comprehensive digital solutions offerings, ranging from numerous minimal invasive and aesthetic prosthetic solutions to intra-oral scanners and clear aligners, and is well positioned to capture the opportunities arising from the accelerated digitalization trend of the dental industry. The Group continues to aggressively gain market share from international and domestic competitors through our established dental ecosystem solutions with a focus on education and digitalization, which is available within close proximity to our clients; effectively meeting our clients’ high expectations through our various onshore and offshore resources. The Group is committed and will continue to equip ourselves to provide the state-of-the-art digital solutions offerings to the dental community in the market.North American BusinessesDuring the year ended 31 December 2025, the North American market recorded a revenue of approximately HK$696.4 million, representing a decrease of approximately HK$55.7 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 18.6% of the Group’s total revenue.A significant portion of our business in the North America region comprises higher-end products manufactured domestically by MicroDental Laboratories, Inc. and its subsidiaries (“MicroDental Group”). While demand for discretionary cosmetic treatments remained soft throughout 2025, our centralized digital workflows and network-wide production oversight enabled us to deliver enhanced service quality and operational efficiencies to our North American customers.Our diversified supply bases in the US, China, Vietnam and Thailand continue to provide greater flexibility to navigate US tariff uncertainties — an advantage that sets us apart from competitors. Although digitalization of imported product lines drove growth in mass market cases, implementation of the US tariff in April 2025 introduced new uncertainties and contributed to a slow growth in sales for our import-focused business unit.Greater China BusinessesFor the year ended 31 December 2025, the Greater China market recorded a revenue of approximately HK$615.4 million, representing a decrease of approximately HK$46.8 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 16.5% of the Group’s total revenue.The Mainland China market faced headwinds from the volume-based procurement policies and a prolonged period of intense price competition and the situation started to stabilize in the second half of 2025. This also led to aggressive promotions for dental implant treatments by Mainland China dental clinics in Hong Kong (which experienced a notable decrease in patient visits in Hong Kong). The Group’s has deliberately pivoted away from low-margin segments and stay focused on serving mid- and high-value customers, ensuring long-term sustainable profitability of the Group’s business.The Group is optimistic in its mid/long-term outlook for this market in particular where the latest procurement-related government measures are expected to (i) standardize the pricing of dental prosthetics and develop price transparency, which would level the playing field; (ii) allow the Group’s leading brand name and reputation to be a key consideration for its client and customer; and (iii) have the Group benefit from its large production team and its ability to allocate resources efficiently according to the customer or client.Australian BusinessesFor the year ended 31 December 2025, the Australian market recorded a revenue of approximately HK$289.1 million, representing an increase of approximately HK$24.4 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 7.7% of the Group’s total revenue. The increase in revenue from Australia reflected a strong uptake of new digital products driven by the digitalization trend in dental industry and the revenue contribution from the acquisition of Digital Sleep which is partially offset by the depreciation of AUD against HK$ by 2.4% compared with the year ended 31 December 2024.Through our various brands, which offer onshore-and offshore-made products, at multiple price points ranging from economy and standard to premium/boutique, the Group is able to effectively penetrate the entire Australian market. We have invested in local production capacity to provide faster service to our customers, and to provide choices around where the products are made. The Group is one of the largest players in the Australian market and is a preferred supplier to the major corporate dental groups in the market.Other MarketsOther markets primarily include Thailand, Indian Ocean countries, Malaysia, Taiwan and Singapore. For the year ended 31 December 2025, these markets recorded a revenue of approximately HK$248.9 million, representing an increase of approximately HK$182.4 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 6.7% of the Group’s total revenue. The increase in revenue from Other markets was primarily driven by the revenue contribution from the newly acquired Hexa Ceram.Future Prospects and StrategiesThe global macroeconomic environment remains uncertain, with geopolitical tensions and potential tariff changes continuing to create headwinds. However, the Group’s geographically diversified production footprint and global distribution network position us strongly to navigate these challenges. Unlike many competitors reliant on single-country manufacturing, our operations across China, Vietnam and Thailand (including the newly acquired Hexa Ceram) provide superior resilience and flexibility. This strategy, combined with our ability to adapt quickly to local market conditions, enables the Group to mitigate risks and capitalize on opportunities across regions.The dental industry has continued to demonstrate remarkable resilience, underpinned by irreversible demographic trends, including aging populations and increasing awareness of oral health, which drive consistent long-term demand. Building on our record 2025 performance, the Group is well placed to sustain momentum and further strengthen its market leadership.Digitalization remains an irreversible industry trend that is accelerating consolidation of the dental prosthetics industry. We are at the forefront of this transformation, with digital solution cases now representing approximately 35–40% of total volume. Our centralized digital workflows, intra-oral scanner partnerships, proprietary solutions and global education centers have enhanced operational efficiency, reduced turnaround times and delivered superior customer experiences. These initiatives create high entry barriers and will continue to drive margin expansion and market share gains in the coming years.Following the successful integration of Hexa Ceram (Thailand’s largest dental laboratory, acquired in January 2025) and Digital Sleep Design (Proprietary nylon oral appliance to treat obstructive sleep apnea), our Southeast Asian presence and specialized capabilities have been significantly strengthened. This expansion, coupled with our diversified supply bases in the US, China, Vietnam, and Thailand, provides enhanced flexibility to address potential trade and geopolitical risks while supporting faster regional delivery.Looking ahead, the Group remains committed to reinforcing its worldwide leading position through a multi-dimensional approach. We will continue to pursue selective acquisitions, joint ventures and partnerships to expand and complement our product offerings, particularly in our high-growth clear aligner, Trioclear, while strengthening our distribution and sales networks. Ongoing investments in mass-scale production facilities, AI, automation, research and development, and digital innovation will drive efficiency gains and secure our position at the forefront of the industry.About Modern Dental GroupModern Dental Group Limited (Stock code: 03600.HK) is a leading global dental prosthetics provider, distributor and consultant with a focus on providing custom-made prostheses to customers in the growing prosthetics industry. Our product portfolio is broadly categorized into three product lines: fixed prosthetic devices, such as crowns and bridges; removable prosthetic devices, such as removable dentures; and other devices, such as orthodontic devices, sports guards, clear aligners, and anti-snoring devices. Modern Dental Group has a global portfolio of respected brands, including Labocast, Permadental and Elysee Dental in Western Europe, YZJ Dental in China, Modern Dental Lab in Hong Kong, Modern Dental USA and MicroDental in the United States, Modern Dental Pacific in Australia and New Zealand, Modern Dental SG in Singapore, Modern Dental TW in Taiwan, Apex Digital Dental in Malaysia and Hexa Ceram in Thailand. We have grown these brands by providing premium and consistent quality products and superior customer service. We have more than 80 service centers in over 28 countries and serve over 35,000 customers. Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com

業績摘要：- 截至2025年12月31日止年度收益約為37.4億港元, 同比增加約11.1%。- 截至2025年12月31日止年度毛利率約為55.8% ；毛利約為20.8億港元，同比增加約15.9%。- 截至2025年12月31日止EBITDA 約為9.4億港元，同比增加約32.4%。- 本集團於截至2025年12月31日止純利約為6.0億港元，同比增加47.7%。- 截至2025年12月31日止每股基本盈利約為63.7港仙，相較去年同期增加約47.5%。- 董事會建議宣派截至 2025年12月31日止年度末期股息每股普通股15.0港仙。- 截至2025年12月31日止年度，本集團於中國內地、泰國及越南生產設施生產之數碼化解決方案個案增加至約1,039,000件，較2024年同期增加32.7%，原因為更多客戶採用口腔內部掃描器。香港, 2026年3月27日 - (亞太商訊) - 2026年3月26日，全球領先之義齒器材供應商 - 現代牙科集團有限公司 (簡稱「現代牙科」或「本集團」，股份代號：03600.HK) 欣然公佈截至2025年12月31日止年度(「年度」) 業績。截至2025年12月31日止年度，在牙科行業數碼化趨勢持續的支持下，本集團的多維度策略及持續提升的營運效率及生產力，使其於本期間的收益、純利及EBITDA數字均創下紀錄新高。雖然期內宏觀經濟環境充滿挑戰，牙科手術的需求普遍疲弱，且貿易戰存在不確定性，然而仍然創下紀錄。本集團利用位於泰國、越南及中國內地的國際生產設施，積極應對前所未有的國際貿易環境。全球數碼化趨勢持續推動義齒行業的整合，使本集團進一步擴大其市場份額。我們持續的數碼轉型措施提升客戶及病人體驗的同時，進一步使本集團在競爭對手中脫穎而出，表現優於同業。本集團的相關基礎仍然穩固，並將全力以赴把握未來機遇。歐洲市場業務截至2025年12月31日止年度，歐洲市場錄得收益約18.9億港元，較去年增加約2.7億港元，此地理市場佔本集團收益總額50.5%。歐洲市場收益增加主要由於新產品的推出(例如數碼化義齒)及我們最先進的數碼化流程，推動銷售訂單量增加。本集團已成為提供全面數碼化解決方案的先驅，範圍涵蓋多項微創及美容義齒解決方案以至口腔內部掃描儀及透明矯正器，本集團已準備好把握牙科行業數碼化趨勢加速帶來的機遇。本集團繼續透過所建立，重點為教育及數碼化且非常鄰近客戶的牙科生態系統解決方案，積極從國際及本地競爭對手取得市場份額；透過不同的境內及境外資源有效地滿足我們客戶的高期望。本集團一直致力並將繼續裝備好自己，為市場上的牙科領域提供最先進的數碼化解決方案。北美市場業務於截至2025年12月31日止年度，北美市場錄得收益約7.0億港元，較去年減少約5,570萬港元，此地理市場佔本集團收益總額約18.6%。我們在北美地區的大部分業務包括MicroDental Laboratories, Inc.及其附屬公司(「MicroDental集團」)在本地製造的高端產品。雖然2025年對主動美容治療的需求仍然疲弱，然而我們的中央化數碼流程及對區內廣泛生產單位的網絡讓我們為北美客戶交出更高服務質素及營運效率。我們位於美國、中國、越南及泰國等地的多元化供應基地，繼續在應對美國關稅的不確定性時帶來更大彈性－此為將我們與競爭對手作區分的優勢。雖然進口產品線的數碼化帶動大型市場個案的增長，然而2025年4月在美國實施的關稅帶來新的不確定性及為我們以進口為主的業務單位的銷售帶來緩慢增長。大中華市場業務截至2025年12月31日止年度，大中華市場錄得收益約6.2億港元，較去年減少約4,685萬港元，此地理市場佔本集團收益總額約16.5%。中國內地市場面對帶量採購政策及價格激烈競爭延長的逆境，而於2025年下半年情況開始穩定。此亦導致中國內地牙科診所積極於香港推廣種植牙治療(香港患者就診人數明顯減少)。本集團有意退出低利潤分部，並專注於中及高價值客戶，確保本集團業務能夠長期及可持續獲利。本集團對此市場的中長期前景感到樂觀，特別是在政府最新的採購相關措施中，預計(i)規範義齒價格及建立價格透明度，平衡中心點；(ii)讓本集團領先的品牌名稱及聲望成為客戶及顧客的主要考量；及(iii)讓本集團從其龐大生產團隊中得益及根據顧客或客戶有效分配資源的能力。澳洲市場業務截至2025年12月31日止年度，澳洲市場錄得收益約2.9億港元，較去年增加約2,438萬港元，此地理市場佔本集團收益總額約7.7%。澳洲的收益錄得增長，反映牙科行業數碼化趨勢帶動大量新的數碼化產品，以及收購Digital Sleep的收益貢獻，但部分被相較於截至2024年12月31日止年度，澳元兌港元貶值2.4%所抵銷。透過我們不同的品牌(可提供境內及境外製造的產品)，憑藉涵蓋從經濟及標準至優質/精品等的多種價位，本集團能夠有效地滲透整個澳洲市場。我們投資於本地產能，以為客戶提供更快捷的服務，並可供選擇產品之生產地。本集團為澳洲市場最大參與者之一並為市場內主要企業牙科團體的首選供應商。其他市場其他市場主要包括泰國、印度洋國家、馬來西亞、台灣及新加坡。截至2025年12月31日止年度，該等市場錄得收益約2.5億港元，較截至2024年12月31日止年度增加約1.8億港元。此地理市場佔本集團收益總額約6.7%。其他市場的收益增加主要由於新收購的Hexa Ceram帶來的收益貢獻所致。未來前景及策略全球宏觀經濟環境仍然不明朗，地緣政治的緊張局勢及關稅的潛在變動繼續營造不利環境。然而，本集團的生產遍及全球各地，而全球分銷網絡讓我們在面對該等挑戰時享有獨特優勢。有別於依賴單一國家生產的一眾競爭對手，我們的營運遍佈中國、越南及泰國(包括新收購的Hexa Ceram)等地，讓我們面對挑戰時能夠進退有據，靈活應變。此策略連同我們快速適應當地市場環境的能力，使本集團降低風險，同時把握各地區的新興機遇。牙科行業繼續展現卓越的適應力，在不可逆轉的人口趨勢下加以突顯，包括人口老化及人們對口腔健康的意識提高，持續帶動義齒的長期需求。本集團建基於2025年創記錄的表現而處於有利位置，能夠保持良好勢頭，同時進一步強化市場的領導地位。行業數碼化勢不可擋，加快義齒行業的整合。我們處於轉型的尖端，目前數碼化解決方案個案佔總銷量約35至40%。我們的中央化數碼工作流程、有關口腔內部掃描儀的夥伴關係、專有的解決方案及全球教育中心有助提升營運效率、縮短處理時間及提供卓越的客戶體驗。有關措施創造高進入門檻，並將於未來數年繼續擴大利潤及增加市場份額。在成功整合於2025年1月收購的泰國最大牙科實驗室Hexa Ceram及Digital Sleep Design(用於治療阻塞性睡眠窒息症的專利尼龍口腔矯正器)後，我們在東南亞地區的影響力及專業能力已經大幅提升。是次擴張連同我們位於美國、中國、越南及泰國等地的多元化供應基地，讓我們在應對潛在的貿易及其他地緣政治風險時帶來更大彈性，同時支持區內快速交付。展望將來，本集團仍然致力透過多角度方針強化其全球領導地位。我們將繼續尋求具針對性的收購、合營企業及夥伴關係，以擴大及補充我們所提供的產品，特別是我們高增長的透明矯正器TrioClear，同時加強我們的分銷及銷售網絡。我們在大型生產設施、AI、自動化、研發及數碼創新方面的持續投資，使效率大幅增高，從而確保我們一直處於行業尖端。關於現代牙科集團現代牙科集團有限公司 (股份代號: 03600.HK) 為全球領先的義齒器材供應商、經銷商和顧問，專注於發展迅速的義齒行業為客戶提供定制式義齒。我們的產品組合大致可分為三類﹕固定義齒器材，例如牙冠及牙橋；活動義齒器材，例如活動義齒；及其他器材，例如正畸類器材、透明牙套、運動防護器及防鼾器。 現代牙科集團擁有多個備受稱許的全球品牌，包括西歐的Labocast、Permadental及Elysee Dental、中國的洋紫荊牙科器材、香港的現代牙科器材、美國的Modern Dental USA及MicroDental、澳洲及新西蘭的Modern Dental Pacific、新加坡的Modern Dental SG、臺灣的 Modern Dental TW、馬來西亞的 Apex Digital Dental及泰國的Hexa Ceram等。我們提供穩定和優質的產品及卓越的客戶服務，令這些公司品牌能茁壯成長。我們於全球超過 28個國家擁有超過 80 家服務中心及服務逾 35,000 名客戶。 Copyright 2026 亞太商訊. All rights reserved. www.acnnewswire.com

HIGHLIGHTS:- Total gross billings amounted to approximately RMB3,955.0 million, representing an increase of approximately 12.8% from approximately RMB3,505.9 million for the corresponding period.- Total revenue was approximately RMB3,430.1 million, representing an increase of approximately 48.7% from approximately RMB2,306.0 million for the corresponding period.- The profit attributable to Shareholders of the Group was approximately RMB921.8 million, representing an increase of approximately 238.5% from approximately RMB272.4 million for the corresponding period.- Non-HKFRS adjusted profit for the year (excluding the share-based compensation expenses) was approximately RMB1,022.5 million, representing an increase of approximately 191.8% from approximately RMB350.5 million for the corresponding period.- Taking into account the financial and cash flow positions of the Group, the Board recommends the payment of a final dividend of approximately HKD168.5 million for the year ended December 31, 2025, representing HKD0.36 per share (in cash), and the proposed final dividend is subject to consideration and approval by Shareholders at the AGM.HONG KONG, Mar 27, 2026 - (ACN Newswire) - JF SmartInvest Holdings Ltd (the “Company” ; together with its subsidiaries, the "Group" or “we”) is pleased to announce its consolidated annual results for the year ended December 31, 2025 (the “Reporting Period”). During the Reporting Period, leveraging its “technology + investment research” dual-drive strategy, the Group achieved outstanding performance. Supported by robust cash flow and profitability, the Board has proposed a final dividend of HK$0.36 per share, bringing the total dividend for the full year to approximately HK$407.4 million when combined with the interim dividend already paid, reflecting its commitment to delivering returns to shareholders.Strong Financial Performance with Substantial Profitability ImprovementDuring the Reporting Period, the Group continued to advance product innovation, AI applications, and investment research capabilities, driving solid growth across its business. Total revenue for the year reached RMB3,430.1 million, representing a YOY increase of 48.7%. Gross profit amounted to RMB2,821.0 million, up 48.9% YOY, while the gross profit margin remained at a high level of 82.2%, indicating the favourable economies of scale and earnings quality of the Group’s business model.In terms of profitability, profit attributable to equity shareholders surged by 238.5% YOY to RMB921.8 million. Excluding share-based compensation expenses, non-HKFRS adjusted profit for the year reached RMB1,022.5 million, representing a YOY increase of 191.8%, fully demonstrating the effective strategy execution and market adaptability of the Group.The Group places great emphasis on shareholder returns. The Board recommends the payment of a final dividend of approximately HKD168.5 million for the year ended December 31, 2025, representing HKD0.36 per share (in cash). Together with the interim dividend of approximately HK$238.9 million already distributed, the total dividend for 2025 will amount to approximately HK$407.4 million. The steady dividend policy fully reflects the Group’s ample cash reserves and its firm confidence in future development prospects.Continued Optimisation of Product Matrix and Enhancement of Diversified Service SystemDuring the Reporting Period, the Group continued to build a diversified product matrix, enriching its product portfolio in response to different customer needs. VIP products 'Stock Navigator, Super Investor' were steadily optimized, with the addition of several quantitative products and AI-powered products. We also launched a 24/7 AI intelligent customer service system, which significantly improved service efficiency. The live streaming system was upgraded, with sessions increasing by 36% YOY and average daily unique viewers exceeding 100,000.Relying on an integrated “AI + content + service + tools” solution, the Enjoy-Stock Pad recorded net sales volume exceeding 75,000 units during the Reporting Period. The Jiuyao Stocks launched over 80 lightweight products, converting professional investment research capabilities into standardised products. The SmartInvest APP completed its strategic transformation from a tool to a platform, with monthly active users increasing by more than 40% YOY and the 30-day retention rate remaining above 50%.The Group further enhanced its product matrix with two new products, Decision Master and Star-tier Services, filling the gap in the mid-tier product system and enabling a seamless trading service experience. Decision Master focuses on three AI+ investment research modules - themes, value investing and quantification - comprehensively enhances investment decision-making capabilities of individual investors. Star-tier Services collaborates with multiple securities brokerages and partners to create a fully integrated closed-loop ecosystem of“tools-services-trading”, serving over 50,000 users during the Reporting Period.Guided by Technological Innovation, Striving Towards “Investment Advisory Intelligent Agent 2.0”The Group regards innovation and technological R&D as its core driving force, accelerating its transformation towards “digital intelligence”, and advancing towards the era of “investment advisory intelligent agent 2.0”. During the Reporting Period, R&D expenses amounted to approximately RMB356 million, with R&D personnel reaching 624, a YOY increase of approximately 42.8%. The Group held 158 software copyrights and patents in AI, big data and product features, with 22 new items added on a year-on-year basis.The self-developed FinSphere Agent Large Model Assistant V3.0 passed the Large Model Assistant Functionality Completeness Test conducted by the China Academy of Information and Communications Technology, becoming the first large-model application in the securities industry. During the Reporting Period, it served approximately 664,000 customers with cumulative services of 22.58 million. The digital intelligent investment robo-advisor “Jiu Ge” served approximately 600,000 customers with cumulative services exceeding 19 million. The Group also launched stock diagnosis intelligent agent 4.0, AI Xiaoce Q&A assistant, and established an intelligent compliance and risk control platform covering the entire business workflow, indicating that the group's AI capabilities have gradually been implemented in core scenarios.To strengthen its technological foundation, the Group established a technology subsidiary, Jiufang Zhiqing, and set its foothold in “Shanghai Foundation Model Innovation Center”, China’s first large model innovation ecosystem community. The subsidiary serves as the Group’s core AI vehicle for operating a native service technology system, promoting the deep application of AI in scenarios such as investment research, investor education, and risk control.Deep-Rooted Investment Research as the Cornerstone, Adhering to Buyer-Side Advisory and Deepening the “1+N” Investment Research SystemThe Group continues to deepen its “1 research institute and N business lines” investment research system, with the JF Financial Research Institute as investment research hub. The Institute has established a pyramidal-structured professional talent echelon led by Chief Economist Dr. Xiao Lisheng, comprising 4 experts, 8 super-IPs and 128 professionals. As of the end of the Reporting Period, the Group had 576 employees holding securities investment advisory qualifications and 2,628 employees holding securities practitioners, maintains a leading team scale and structure in the industry.During the Reporting Period, The Institute conducted more than 300 research activities, covering more than 2,000 listed companies. The Institute authored approximately 1,200 in-depth research reports and 45 sets of thematic courses with a total duration of 2,000 minutes, continuously enhancing the professional capabilities of buyer-side consultants.Multi-Dimensional, Full-Funnel Traffic Operation to Unlock New Growth DimensionsDriven by AI technology, the Group positions refined MCN-based traffic operations as a central hub connecting users with its business, building an integrated, synergistic omni-channel traffic ecosystem comprising “public-domain MCN (multi-platform) + private-domain + proprietary APP”. On the technological front, the Group applied AIGC to restructure content production, shifting from manual creation to “human-machine collaboration” model, and established a data flywheel integrating “advertising data, model training and operational automation”. During the Reporting Period, the Group consolidated its leading position on online short-video and live streaming platforms’ operations, established a multi-platform coordinated traffic matrix, and developed a multi-tiered, high-quality content ecosystem. It also pioneered e-commerce models for the Enjoy-Stock Pad and AppStore models for the APP, driving deep integration between traffic operations and product features.Future OutlookMr. Chen Wenbin, chairman of the Board and chief executive officer of JF SmartInvest Holdings Ltd, said: “In 2025, we remained committed to the dual-drive strategy of ‘technology + investment research’. Not only did we achieve leapfrog growth in performance, but we also successfully led the industry into the era of ‘Investment Advisor Agent 2.0’. Leveraging artificial intelligence and big data technologies, we developed AI products such as the JF Robo-Advisor, FinSphere Agent and FinSphere Report, achieving industry-leading innovations and scenario-based applications, helping users accomplish the critical transition from ‘cognitive improvement’ to ‘decision optimisation’. At the same time, we transformed our professional investment research capabilities into easily accessible lightweight services, realising a strategic shift ‘from tool to platform’. We uphold the principles of rational investing, value investing and long-term investing, assisting clients in developing sound investment philosophies.“In the future, the Group will focus on four key strategic dimensions. First, deepening AI-driven empowerment across all scenarios, accelerating the iteration of AI agents and their commercialisation on the consumer side, and driving the Group’s digital and intelligent transformation. Second, leveraging Forthright Securities and Forthright Capital’s licenses, advancing the globalisation strategy by exporting the Jiufang’s core models, accelerating overseas business expansion. Meanwhile, promoting license upgrading and strategic investment layout to further improve the construction of digital asset infrastructure. Third, strengthening product-driven business diversification and synergies, deepening cooperation with licensed financial institutions such as securities brokerages, and building a service closed loop covering pre-investment, in-investment and post-investment. Fourth, continuing to optimize the customer operation system, unlocking the value of traffic through full-funnel traffic initiatives, and achieving long-term customer retention. We are dedicated to making investing simpler and more professional while enhancing investors’ sense of fulfillment in investment and wealth management.”About JF SmartInvest Holdings Ltd (Stock Code: 9636)JF SmartInvest Holdings Ltd is a new generation stock investment assistant. The Company is engaged in the provision of equity investment instruments, securities investment advisory, investor education and other services to individual investors. The products include stock quote software, the AI Stock Machine, Stock Navigator, Super Investor and Jiuyao Stocks. The Company adopts the technology + investment research model, develops JF Robo-Advisor, FinSphere Agent, FinSphere Report and other products based on artificial intelligence (AI) and big data technology, which are applied to the industry in terms of innovative practice and scenario application.For enquiries, please contact:Financial PR (HK) LimitedEmail: ir@financialpr.hkTel: 852 2610 0846Fax: 852 2610 0842 Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com

摘要：- 總訂單金額約為人民幣3,955.0百萬元，較同期的約人民幣3,505.9百萬元增加約12.8%。- 總收益約為人民幣3,430.1百萬元，較同期的約人民幣2,306.0百萬元增加約48.7%。- 股東應佔溢利約為人民幣921.8百萬元，較同期的約人民幣272.4百萬元增加約238.5%。- 非香港財務報告準則下經調整年內溢利（剔除以股份為基礎的薪酬開支）約人民幣1,022.5百萬元，較同期的約人民幣350.5百萬元增加約191.8%。- 董事會建議派發末期股息約168.5百萬港元，即每股0.36港元（現金），建議末期股息須待股東於股東週年大會上審議及批准。香港, 2026年3月27日 - (亞太商訊) - 九方智投控股有限公司（「九方智投控股」或「公司」；及其附屬公司統稱「本集團」或「我們」）欣然宣佈截至2025年12月31日止年度（「2025年」或「報告期內」）之綜合年度業績。報告期內，本集團踐行「科技＋投研」雙輪驅動戰略，錄得良好業績表現。基於強勁的現金流與盈利表現，董事會建議派發末期股息每股0.36港元，連同已派發的中期股息，全年累計派息總額約407.4百萬港元，積極回報股東支持。財務表現強勁 盈利能力大幅提升報告期內，本集團持續推進產品創新、AI應用及投研能力建設，帶動整體業務穩健增長。年度總收益達人民幣3,430.1百萬元，同比增長48.7%；毛利達人民幣2,821.0百萬元，同比增長48.9%，毛利率維持在82.2%的高水平，反映本集團業務模式具備良好的規模效益及盈利質量。盈利表現方面，股東應佔溢利同比大幅上升238.5%至人民幣921.8百萬元。若剔除以股份為基礎的薪酬開支，按非香港財務報告準則計算的經調整年內溢利達人民幣1,022.5百萬元，同比增長191.8%，顯示公司戰略執行持續見效，並具備良好的市場應變能力。本集團始終重視股東回報，建議派發2025年度末期股息每股0.36港元，派息總額約168.5百萬港元。連同已派發的中期股息約238.9百萬港元，本集團2025年全年派息總額約為407.4百萬港元。穩健的派息政策充分反映集團充裕的現金儲備，以及對未來發展前景的堅定信心。持續優化產品矩陣 推動多元化服務體系建設報告期內，本集團持續構建多元化產品矩陣，圍繞不同客群需求不斷豐富產品組合。VIP產品（股道領航、超級投資家）穩步迭代，新增多款量化及AI產品，並上線7×24小時AI智能客服，進一步提升服務效率；直播體系亦全面升級，場次同比增加36%，日均總UV超過10萬。依託「硬件＋AI＋內容＋服務」一體化方案，「易知股道」AI股票機於報告期內淨銷量超7.5萬台，用戶使用時長及黏性均保持良好水平；「九爻股」累計推出80餘款輕量化產品，將專業投研能力轉化為標準化產品，有效降低個人投資者參與門檻；「九方智投APP」則實現由工具向平台的戰略轉型，報告期內月活用戶同比增長超40%，30日留存率維持在50%以上，整體用戶黏性持續提升。此外，本集團進一步完善產品矩陣，推出「決策大師」及「星級服務」兩大新產品，填補中端產品空缺，跑通交易鏈路。其中，「決策大師」聚焦AI＋題材、價投及量化三大投研模組，協助個人投資者提升自主決策能力；「星級服務」則聯動券商及合作夥伴，打造「工具—服務—交易」一體化生態閉環，報告期內服務用戶規模超過5萬。以科技創新為核心 全力邁向「投顧智能體2.0」本集團視創新和技術研發為核心驅動力，全速推進全面「數智化」戰略，深耕證券領域「人工智能+」應用，全力邁向「投顧智能體2.0」時代。報告期內，研發投入約人民幣356百萬元，研發人員達624人，較同期增長約42.8%；在人工智能、大數據及產品功能等領域共擁有軟件著作權及專利158件，同比新增22件。自研的「九方靈犀」大模型助手V3.0通過中國信息通信研究院大模型助手功能完備性測試，成為證券行業首個獲此認證的大模型應用。報告期內，該產品服務客戶約66.4萬人，累計服務達2,258萬次；智能投顧數字人「九哥」服務客戶約60萬人，累計服務超1,900萬次。公司亦推出診股智能體4.0智能體工具、AI小策問答助手，構建了覆蓋業務全流程的智能合規風控平台，逐步將AI能力深度賦能各大業務核心場景並形成規模化應用。為進一步強化技術基礎，本集團設立科技子公司九方智擎並入駐全國首個大模型創新生態特區「模速空間」，作為集團AI技術核心載體，搭載原生服務技術體系，推動AI在投研、投教、風控等場景深度落地。以深度投研為基石 堅持買方投顧 深化「1+N」投研體系本集團持續深化「1個研究所，N條業務線」投研體系，以九方金融研究所為投研中樞，推動專業能力滲透至業務全流程。研究所目前已建立以首席經濟學家肖立晟博士為核心，聯動4名專家、8名超級IP及128名專業人員組成的金字塔式團隊。截至報告期末，本集團擁有576名具備證券投資顧問資格及2,628名具備證券業資格的員工，專業團隊規模及結構均保持行業領先。報告期內，研究所完成上市公司、行業論壇及券商策略會等調研超300場，研究覆蓋約2,000家上市公司，並深度跟蹤其中1,500家；全年累計撰寫約1,200篇深度報告，並開發45套專題課程，總時長達2,000分鐘，持續鞏固買方投顧專業能力。多維全域流量運營 拓展業務增長新維度本集團以AI技術為核心驅動力，將MCN精細化流量運營定位為連接用戶與業務的核心樞紐，構建「公域MCN＋私域＋自有APP」三位一體、協同聯動的全域流量體系。技術層面，公司深度應用AIGC重構內容生產，從人工創作轉向「人機協同」，並搭建起「投放數據－模型訓練－運營自動化」的數據飛輪。報告期內，本集團持續鞏固線上短視頻直播平台的領先運營優勢，搭建多平台協同流量矩陣，打造多層次優質內容生態。同時創新探索AI股票機電商模式與APP應用市場，推動流量運營與產品特性深度適配。展望未來九方智投控股董事會主席及首席執行官陳文彬先生表示：「2025年，我們始終堅持『科技＋投研』雙輪驅動策略。我們不僅實現了業績的跨越式增長，更成功引領行業邁向『投顧智能2.0』時代。基於人工智能與大數據技術，我們研發了九方智能投顧數字人、九方靈犀、九方智研等AI產品，實現了行業領先的創新實踐與場景應用，助力用戶完成從『認知提升』到『決策優化』的關鍵轉化。同時，我們將專業的投研能力轉化為觸手可及的輕量化服務，實現了由『工具向平台』的戰略轉型。我們貫徹理性投資、價值投資和長期投資理念，幫助客戶構建正確的投資觀。未來，本集團將聚焦四大戰略維度：第一，深化AI全場景賦能，加速投顧智能體迭代與C端商業化落地，驅動公司全面數智化轉型；第二，充分利用方德證券、方德資本牌照資源優勢，深化全球化戰略佈局，輸出九方核心模式，加速海外業務拓展，並推進數字資產相關牌照升級與戰略投資，完善數字資產基礎設施搭建；第三，強化產品力驅動多元協同，深化與券商等持牌金融機構的合作，構建涵蓋投前、投中、投後的服務閉環；第四，持續優化客戶經營體系，透過全域化流量佈局深挖流量價值，實現客戶長效留存。我們致力于让投資理財變得更簡單、更專業、提升投资理财的幸福感。」關於九方智投控股有限公司九方智投控股有限公司作為新一代股票投資助手，面向廣大個人投資者提供股票投資工具、證券投資顧問、投資者教育等服務，相繼推出股票行情軟件、AI股票機、股道領航、超級投資家、九爻股等產品。該公司通過「科技＋投研」模式，基於人工智能（AI）與大數據技術研發九方智能投顧數字人、九方靈犀、九方智研等AI產品，實現行業創新實踐與場景應用。如有垂詢，請聯絡：金融公關（香港）有限公司電郵：ir@financialpr.hk電話：852 2610 0846傳真：852 2610 0842 Copyright 2026 亞太商訊. All rights reserved. www.acnnewswire.com

SINGAPORE, Mar 27, 2026 - (ACN Newswire) - Choosing where to place your savings in Singapore is an important financial decision that requires careful consideration. With many banks offering different types of accounts, it is easy to get confused. However, picking the right one is the first step to reaching your financial goals, whether you are saving for a dream wedding, a new home, or a retirement fund.The good news is that you no longer need to spend a whole afternoon waiting at a bank branch. You can now open a bank account online in just a few minutes using your phone or computer. Here is a simple guide to help you choose the best account for your needs in 2026.Identify Your Financial HabitsBefore focusing on interest rates, consider how you manage your money on a daily basis. Savings accounts in Singapore usually fall into two categories:The Active Saver: These accounts give you high interest rates, but you have to make a few mandatory transactions each month. Usually, you need to credit your salary and spend a set amount on your credit card.The Passive Saver: These accounts help you earn bonus interest just for keeping your money in the account and letting it grow. You do not need to worry about credit card spending or paying bills.Compare Interest RatesBefore opening a bank account online, make sure you compare the interest rates. Many basic accounts offer low interest rates. To make your money grow, you should look for bonus interest.For example, a high-interest account can offer between 2% and 5% depending on the rules you follow. If you have SGD 50,000, the difference between a basic account and a high-interest one could be hundreds of dollars in extra cash every year. Always check the effective interest rate, which tells you the real amount you will earn after all the levels are counted.Look for Welcome PromotionsBanks in Singapore are always competing for your business. When you open a bank account online, you can often grab a welcome gift, such as cash credits or rewards. These promotions are a great way to get a head start on your savings. Just make sure to check the dates, as many of these flash deals only last for a few months.Check the Fees and MinimumsEven a great account can lose you money if you are not careful about fees. Before you sign up, check for these three things:Minimum balance: Most accounts require maintaining a certain amount of money in the account at all times. If the balance drops below this limit, the bank may charge you a monthly fee.Initial deposit: Some accounts require at least SGD 1,000 to get started.ATM access: Make sure the bank has plenty of ATMs near your home or office so you do not get charged for using the machine of another bank.Open an Account OnlineOnce you have picked the right account, the final step is to fill out your application. In Singapore, you can use Singpass MyInfo to fill out your application automatically.When you open a bank account online, your details, such as your NRIC, address, and income, are pulled directly from the government database, thus reducing paperwork. Most accounts are approved almost instantly, and you can start using your new digital card right away.Final ThoughtsChoosing a savings account is not just about finding the highest interest rate. It is about finding the one that fits how you live. If you are a busy professional who already uses a credit card, an active account is perfect. If you just want to set your money aside and forget it, a passive account is better.By taking 10 minutes to compare your options today, you can ensure that every dollar you earn works as hard as you do.Disclaimer: This article is for general information only and does not have any regard to the specific investment objectives, financial situation and particular needs of any specific person. The views expressed in this article are solely those of the author. This article shall not be regarded as an offer, recommendation, solicitation or advice. You may wish to consult your own professional advisers about this article, in particular, a financial professional before making financial decisions. Any past events, trends and/or performance referred to in this article may not necessarily be indicative of future events, trends or performance. This article is based on certain assumptions and reflects prevailing conditions as at the time of publication, which are subject to change at any time without notice. The author and publisher of this article as well as any other parties associated with this article make no representation or warranty of any kind, whether express, implied or statutory, in respect of this article and accept no liability or responsibility for the completeness or accuracy of this article or any error, inaccuracy or omission relating to this article and/or any consequence, injury, loss or damage howsoever suffered by any person relating to this article, in particular, arising from any reliance by any person on this article. Publishers or platforms may be compensated for access to third party websites.Contact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com

香港, 2026年3月27日 - (亞太商訊) - 近日，2026中關村論壇年會在北京隆重舉行。作為國家級科技創新交流合作平臺的重要參與者，百望股份受邀出席本次國家級科技創新交流盛會，並在"東盟創新合作發展論壇"中發表了重磅主題演講。論壇上，百望股份聚焦跨境貿易合規痛點，推介全球智能稅務合規平臺Tax Swift。它內置百望自研的AI稅務引擎、百望指數與國家適配器，依托覆蓋全球的稅務規則知識庫，動態監控、AI分析、自動更新，打造起全球貿易的"合規路由器"，為國際經貿合作注入合規新動能。論壇聚焦科技創新，跨境合規成全球貿易核心命題2026年中關村論壇年會，是經國務院批准、以"科技創新與產業創新深度融合"為年度主題，由科技部、國家發展改革委、工業和信息化部、國家國資委、中國科學院、中國工程院、中國科協和北京市政府共同主辦。大會匯聚了100多個國家和地區的全球頂尖科學家、企業家及國際組織代表，上千名嘉賓共同搭建起中國與世界科技創新交流的橋梁。作為本次中關村論壇的重要平行論壇，東盟創新合作發展論壇聚焦中國與東盟科技創新協同、產業融合發展、跨境貿易便利化等核心議題，匯聚東盟各國政、產、學、研各界代表，交流研判破解區域經貿合作中的共性難題。在主題演講環節，百望股份圍繞著"AI賦能中企出海：構建全球化合規新底座"展開了深度分享。當前，全球貿易一體化進程不斷加快，跨國經營的業務蓬勃發展，但稅務合規難題始終是制約全球貿易高效推進的關鍵瓶頸。尤其是東盟這樣的活力經濟體，區域內各國經貿往來頻繁，跨境交易規模持續攀升，市場主體對於交易效率、交易合規有著更高的需求和更迫切的期待，而區域內各國稅務政策、技術標准的差異，卻成為了制約中國-東盟跨境貿易提質增效的重要因素。從實踐來看，國際貿易稅務合規難題呈現多元化、複雜化態勢：- 語言與格式壁壘凸顯，不同標准、規範讓企業票據解讀成本高、理解易出偏差；- 各國財稅政策碎片化嚴重，差異性的稅種、稅率、申報流程，讓企業難以精准掌握；- 技術標准不統一，系統接口、數據傳輸缺乏規範，各類操作繁瑣且效率低下；- 跨境交易鏈條長、涉及主體多，企業難以實現全流程風險檢測；這些難題不僅增加了企業跨境經營的成本，更成為制約企業融入全球產業鏈、拓展國際市場的關鍵瓶頸。百望股份的Tax Swift平臺，正是破解合規困境、保駕跨境貿易的全新技術創新，尤其為中國-東盟跨境貿易合規發展提供了高效可行的思路。Tax Swift重磅亮相，全鏈路一站式賦能國際貿易合規作為百望股份的深耕全球稅務合規領域、布局國際化市場的核心成果，Tax Swift一次適配，就可幫助企業構建起覆蓋"票據處理-納稅申報-風險管控"的全鏈路跨境稅務合規服務體系：一是全球AI全鏈路票據處理能力，可打破語言與格式壁壘。國際化引擎、發票引擎、稅務引擎與國家適配器，四重引擎自動協同運轉，完成智能算稅、智能識別等，一套架構適配全球業務場景。企業無需手動幹預任何細節，即可完成多語言、多幣種、多時區的票據管理工作，完美適配東盟各國票據規範與業務場景。二是全球AI一鍵申報，打通跨境稅務申報便捷通道。Tax Swift現已與20多國國稅局直連，全球稅務規則知識庫動態更新、AI分析引擎自動掃描規則變化，聯動發票識別引擎與全球交易計稅規則引擎實時響應，將全球申報工作壓縮成一個動作：一鍵登錄，自動填飽，實時同步狀態，可大幅提升東盟跨境貿易稅務申報效率。三是全球AI稅務顧問，提供全周期政策支撐。平臺內置超3萬條國際財稅規則，覆蓋200+國家稅種與費金，通過實時聯動發票引擎與稅務引擎，實現AI自動解讀、自動更新，及時識別和處置異常變化，幫助企業精准把握區域政策動態、規避合規風險，尤其針對東盟各國稅務政策的更新與調整實現實時響應。三大AI能力模塊的協同運作，為企業建立起全球合規洞察的能力，構築起清晰可控的合規管理邊界。當前，全球貿易格局深度調整，合規已成為企業跨境經營的核心競爭力，百望股份"貿易無國界、納稅有主權"的理念，精准契合了出海企業的合規需求。依托全球化戰略布局，百望股份持續推進TaxSwift產品迭代落地，自2025年8月啟動以來，產品已完成1.0版本全球電子發票布局，並在2026年加速海外數據中心與算力中心部署，加速東南亞、歐盟、中東等區域市場的拓展，向著建設覆蓋80+CTC國家的全球AI票稅合規平臺快速演進。而東盟作為百望股份全球化出海的先鋒陣地，憑借區域內旺盛的跨境貿易合規需求，成為 Tax Swift 落地應用的核心市場，已有眾多企業與百望股份達成深度合作，其中越南、新加坡、印度尼西亞等東盟國家的企業、高校更是與百望攜手，共同探索跨境稅務合規的數智化解決方案，讓 Tax Swift的技術能力與服務體系更好地適配東盟市場需求。依托中關村論壇及東盟創新合作發展論壇的開放平臺，更多國際嘉賓尤其是東盟各國代表，對百望股份的數智解決方案有了進一步了解。深耕財稅數智領域十餘年，百望股份已經累計處理發票數量逾260億張，對應交易總額高達1188.0萬億元，服務的納稅人識別號數量更是突破了9640萬家，這些豐富的實踐經驗與數據智能領域的深厚沉澱，贏得了與會嘉賓產生了高度關注與廣泛認可。未來，百望股份將持續深化Tax Swift平臺的迭代升級，重點打磨適配東盟市場的產品能力與服務體系，打造一流的全球稅務合規智能體平臺，進一步拓展全球服務範圍，幫助更多跨境經營的國際企業開拓發展、贏得未來！ Copyright 2026 亞太商訊. All rights reserved. www.acnnewswire.com

- Annual sales of HuaTangNing exceeded 4 million packs, a year-on-year increase of 91%, with revenues reaching RMB 492.9 million, a year-on-year increase of 93%, marking outstanding results from the Company’s fully independent commercialization operation.- Delivered record financial performance, with profit before tax reaching RMB 1,106.4 million; maintained a robust bank balance and cash position of RMB 1,092.3 million at year-end, laying a solid foundation for sustainable operations and growth.- Gross margins rose to 56.9%, and selling expenses as a percentage of revenue were optimized to 33.6% from 59.9%, significantly enhancing profitability.- HuaTangNing renewed its listing in the new National Reimbursement Drug List (NRDL) at the same price in 2025 for the calendar years 2026 and 2027, reaffirming its clinical and innovative value.- With the approval of PTE, market exclusivity in China granted another 5 years to April 2034, further strengthening commercial certainty.- Dorzagliatin was approved for commercialization in Hong Kong as HYHOMSIS®, accelerating its global expansion toward South-East Asia.- Multiple real-world evidence published to demonstrate therapeutic advantage of dorzagliatin.- Continuous expansion of therapeutic potential of glucose homeostasis and initiation of new first-in-disease indications study covering diabetes prevention, rare diseases, mild cognition impairment and frailty.SHANGHAI, Mar 27, 2026 - (ACN Newswire) – Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552) announces the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2025 (the “Reporting Period”). During the Reporting Period, the commercialization of HuaTangNing (dorzagliatin tablets), the Company’s core product – the global first-in-class innovative anti-diabetes medicine, glucokinase activator (GKA) – advanced comprehensively across all fronts, the Company’s independent commercialization team was efficiently and seamlessly established in its first year of operations, the Company’s R&D pipeline continued to be enriched, and the Company’s financial performance achieved a historic breakthrough, successfully entering a new stage of profitability, injecting strong momentum into the innovative development of the global diabetes treatment field.Dr. Li CHEN, Founder and CEO of Hua Medicine, stated: “2025 is a remarkable year in the commercialization operation of Hua Medicine. The Company has successfully advanced from R&D to commercialization driven organization and achieved the fully independent capacity in commercialization of global first in class novel glucose homeostasis regulator HuaTangNing. With strong market execution and product competitiveness, we have achieved nearly triple-digit growth in sales volume and revenue over 2024 when the commercialization was farmed out to sales and marketing partners. At the same time, the Company has made key progress in global market expansion through registration of drozagliatin in Hong Kong and position it toward 700 M population in south-east Asia. We continue to expand the clinical application of glucose homeostasis regulation technology and engage in new indications such as early-stage Alzheimer’s disease and Frailty. The first-in-disease efforts in GCK-MODY and Frailty set the new innovation course of Hua Medicine in the next 5 years.” Business Highlights and Operational Progress- Fully Powered Commercialization, Historic Breakthrough in ProfitabilityOn January 1, 2025, the Company assumed full responsibility for the commercialization of HuaTangNing, allowing the company to consolidate both operational and strategic control over market execution in China. The Company successfully built a professional sales team covering 10 sales regions around the country, focusing on marketing, medical affairs and commercial operation. Through an AI-empowered digital commercialization platform, operational efficiency and sales productivity were greatly enhanced, injecting new vitality into the Company’s commercial development.Reimbursement coverage under the NRDL has significantly increased accessibility, especially in Tier 2 and Tier 3 hospitals, and played a critical role in accelerating patient adoption. Since its launch in October 2022, HuaTangNing has been prescribed to over 500,000 patients through 3,000+ hospitals, community centers, pharmacies and online channels.Sales performance exceeded expectations, with 4.011 million packs of HuaTangNing sold during the reporting period, representing a 91% increase over the fiscal year 2024. This growth was achieved at the same price for both periods, underscoring strong demand and successful execution of Hua’s commercial strategy.In terms of profitability, the Company’s gross profit reached approximately RMB280.4 million, a year-on-year increase of 125%. Thanks to expanded production scale and optimized manufacturing processes, the Company’s gross margin improved to 56.9%, increasing by 8.2 percentage points as compared to 48.7% for the year of 2024. Selling expenses increased only by RMB12.3 million to RMB165.5 million, reflecting a significant positive trend towards profitability when our selling expenses in the 2025 fiscal year represents only 33.6% of revenue, whereas in the 2024 fiscal year, our selling expenses represented approximately 59.9% of revenue. In fiscal year 2025, our commercialization efforts achieved profits of approximately RMB114.9 million (as defined by gross profits less selling expenses). Although we expect to continue to increase personnel to our commercialization team, we expect this profitability trend in our commercial operations in mainland China to continue.Following the termination of the collaboration with Bayer at the end of 2024, dorzagliatin achieved a record-high sales volume. Profit before tax increased to RMB1,106.4 million for the fiscal year 2025. We ended fiscal year 2025 with a cash position of approximately RMB1,092.3 million.- Accelerated Global Layout, Strengthened Core Rights and InterestsThe Company took a key step in global expansion. On February 27, 2026, dorzagliatin (trade name: MYHOMSIS®, was successfully approved for marketing by the Hong Kong regulatory authority. The Company plans to officially launch the product in the Hong Kong market by the middle of 2026 and further expand to Asian regions. In addition, the Company submitted a new drug registration application in Macau in 2025.The Company also made new progress in intellectual property protection. In February 2026, the patent term extension (PTE) application for dorzagliatin was formally approved by the China National Intellectual Property Administration, thereby the core patent protection period of dorzagliatin extended to April 2034 and an additional 5-year market exclusivity obtained, which provides a strong guarantee for the product’s long-term market competition.In 2025, dorzagliatin was recognized as national innovation and an effective therapy for chronic diseases by the regulatory authorities in China. Accordingly, the same NRDL price was offered for the calendar years 2026 and 2027. Reimbursement coverage under the NRDL has significantly increased accessibility, especially in Tier 2 and Tier 3 hospitals, and played a critical role in accelerating patient adoption. The Company will continue to safeguard the product’s market competitiveness and patient accessibility and accelerate the popularization of the drug among patients.- Advancement of Real-World Studies, Continuous Validation of Clinical ValueReal-world evidence (RWE) studies continue to corroborate the key role of dorzagliatin in improving glucose-dependent pancreatic islet secretion function, and demonstrate its efficacy in diabetes prevention, remission, and delaying or preventing diabetes complications.The RWE study sponsored by Hua Medicine HMM0701 with 380 T2D patients was fully enrolled in 2025. The interim analysis, as reported at the 2025 American Diabetes Association (ADA), showed that 86% of such patients were taking two or more antidiabetic drugs and 41% of such patients were using insulin. After a 6-month treatment, a significant improvement of glycemic control was observed with HbA1c reduction from 8.1% to 7.3% with the mean time-in-range (TIR) levels increasing to over 70%. Thus far, the studies have demonstrated that when dorzagliatin is administered in combination with other antidiabetic drugs, such patients have experienced significantly improved post-meal glucose levels and improved β-cell function.Separately, a mechanistic study with dorzagliatin (employing double-tracer measurement) was conducted in the United States to provide scientific evidence of hepatic glycogen formation in T2D patients with an average of 17 years of diagnosed diabetes. In this study, patients were treated with dorzagliatin twice daily for 6 weeks. The results showed that dorzagliatin increased direct glucose flux to hepatic glycogen implying the improvement of restoration of hepatic Glucokinase (GK) function. Together with the clinical research data that dorzagliatin improves early phase insulin release and GLP-1 secretion, recovery of hepatic glycogen synthesis in T2D patients offers an important path in controlling post-meal glucose excursion and provides a unique opportunity in controlling diabetes complications, such as diabetes kidney diseases and mild cognition impairment.The RWE sponsored by Hua Medicine (HMM0601) has completed clinical trials with over 2,000 subjects, with average diabetes duration of 7.9 years and above 30% having disease duration more than 10 years. The initial results suggest that dorzagliatin is safe and well tolerated in Chinese T2DM patients. There were no new adverse effects observed in the study and the incident rate remains as low as what was observed in Phase III clinical trials. Patient adherence was generally high, with a mean adherence rate of approximately 95%. In this study, 80% of the participants have used one or more oral anti-diabetes medicine, and 20% used insulin. Dorzagliatin demonstrated good efficacy and safety not only in the overall population but also in elderly, obese, and hyperglycemic patient populations, whether used as monotherapy or in combination with metformin, SGLT2 inhibitors, insulin, and other medications. The topline results will be reported at the 2026 American Diabetes Association.- Deepened Clinical R&D, Continuous Expansion of New IndicationsNew Indication for Dorzagliatin – MODY-2 Patients.Medical experts in mainland China and Hong Kong have conducted independent clinical and preclinical studies of dorzagliatin for MODY-2 treatment. MODY-2, also called GCK-MODY, is a monogenic disease in which patients have a genetic defect of glucokinase gene (GCK) which results in elevated blood glucose and significant reduction of the second phase insulin secretion. The population of GCK-MODY patients is approximately 1.7 million in China. These patients are diagnosed with diabetes at a young age and represent an unmet medical need given that currently available medications are not effective. In clinical studies with MODY-2 patients, China investigators have reported that dorzagliatin is effective in reducing blood glucose levels to normal levels in MODY-2 patients who previously failed to manage their elevated blood glucose levels when treated with metformin, TZD, DPP-IV inhibitors, and SGLT-2 inhibitors. Additional results demonstrated that a single dose of dorzagliatin improved overall glucose sensitivity and second phase insulin secretion significantly in GCK-MODY patients, suggesting a unique mechanism of action of dorzagliatin to regulate GLP-1 secretion. Based on such results, Hua Medicine has communicated and reached a consensus with the CDE at NMPA to file the IND submission of dorzagliatin for MODY-2 patients in 2026.Dorzagliatin for Diabetes Prevention.Prevention of diabetes is an important focus at Hua Medicine. There are approximately 1.12 billion people living with prediabetes worldwide. We have initiated SENSITIZE 3 clinical study in Hong Kong in pre-diabetic (IGT) subjects and in early diabetes patients. These studies represent first-in-disease studies. In this double-blinded placebo-controlled study, we will evaluate the blood glucose management and pancreatic function under IVGTT and OGTT conditions to better define the clinical treatment baseline and endpoints. We expect to complete this study in 2026 and explore the opportunity to file IND applications of dorzagliatin for diabetes prevention in China and Asian Pacific regions thereafter. Dorzagliatin for Neurodegenerative Diseases.MCI shows approximately 15.5% prevalence among elderly people in China and approximately 22% in the US, and is common in T2D patients with a 45% incidence rate. The development of dorzagliatin for neurodegenerative disease is a new focus in our drug discovery efforts. Through the Genome-Wide Association Study (GWAS) and Mendelian Randomization (MR) study, we have realized the important role of GCK gene activation in the prevention of memory loss and cognitive impairment in humans. It has also come to our attention that post-meal glucose excursion is closely related to Alzheimer disease and dementia. The bio-energy balance in the brain is largely dependent on the glucose homeostasis control in the peripheral organ and the neural network communication in the central and peripheral system via spatial temporal management. Impaired glucose homeostasis and diabetes conditions result in a reduction of glucose transporter expression and insulin receptor expression in the brain, which can be prevented by low dose dorzagliatin. We have realized the potential of dorzagliatin in the treatment of mild cognitive impairment (MCI) and will initiate these first-in-disease clinical studies in the future.Dorzagliatin for Frailty.Frailty is an age-related geriatric syndrome characterized by reduced tolerance to internal and external stressors. Approximately 17% of Americans and 11% of Asians over the age of 50 suffer from frailty, while pre-frailty affects roughly 50% and 47% of these populations, respectively. It is not a single-organ disease, but the consequence of dysregulated multisystem homeostasis. Genetic evidence supports the causal effects of glucokinase (GK) activation on lowering frailty risk. We plan to initiate clinical studies in the future to advance dorzagliatin’s application in frailty.Development of combination therapy for diabetes and complications.Dorzagliatin rescues pancreatic function in glucose insulin secretion and GLP-1 secretion, as evidenced by clinical and basic research results. It also improves hepatic insulin sensitivity and reduces hepatic insulin resistance through recovery of hepatic glycogen synthesis in T2D patients. The combination of dorzagliatin with DPP-IV inhibitors, SGLT-2 inhibitors, and GLP-1 agonists have demonstrated effective regulation of lipid metabolism. Studies in combination with anticancer PI3K inhibitors have also offered unique benefits for glucose homeostasis management.- Diversified Product Pipeline, Innovative Layout for Future GrowthHua Medicine continues to enrich its pipeline layout based on core products. The Company has accelerated the R&D of a fixed-dose combination (FDC) of dorzagliatin and metformin as a twice-daily therapy for Type 2 diabetes patients with inadequate glycemic control on metformin alone, to further improve patient medication compliance. The product is supported by the strong results of the loose-dose combination in both Phase III clinical trials and real-world use. The Company has submitted an IND application to NMPA, and the GMP commercial manufacturing process has been successfully carried out, preparing for the pivotal bioequivalence study for NDA filing in 2027. Clinical studies have shown that the combination of dorzagliatin and metformin can better control blood glucose, reduce postprandial blood glucose and improve fasting blood glucose, providing new clinical value for optimizing blood glucose homeostasis endpoints.We have advanced our 2nd generation GKA as a once daily therapy for patients with obesity, leveraging dorzagliatin effects in improved glucose-stimulated GLP-1 secretion in the pancreas and in the intestine. The MAD study of the 2nd generation GKA was initiated in the United States with first-patient-in in December 2025, and we expect to report topline data by the middle of 2026.Meanwhile, the Company is also exploring combination therapy regimens of dorzagliatin with GLP-1 receptor agonists, SGLT-2 inhibitors and other drugs. In a recently published clinical trial in China, researchers reported the superior benefits of our dorzagliatin in combination with semaglutide as compared to semaglutide alone in a 12-week study. The combination group showed superior results across several key measures, including glycemic control, bodyweight related indicators and β-cell function.Financial Summary- Revenue generated by the Company was approximately RMB 492.9 million from the sale of approximately 4.011 million packs of HuaTangNing, increases of approximately 93% and 91% respectively, as compared with the year ended December 31, 2024.- Gross profit generated by the Company for the year ended December 31, 2025, was approximately RMB280.4 million, representing an increase of approximately 125%, as compared with the year ended December 31, 2024, and gross margins rose to 56.9%.- Profit before tax increased by approximately 542% to approximately RMB1,106.4 million for the year ended December 31, 2025, as compared with the year ended December 31, 2024.- Bank balances and cash position was approximately RMB1,092.3 million as of December 31, 2025.- Expenditures incurred by the Company for the year ended December 31, 2025, were approximately RMB433.4 million.Forward-Looking StatementsThis document contains statements regarding Hua Medicine's and its products' future expectations, plans and prospects. Such forward-looking statements relate only to events or information as of the date on which the statements are made in this document and are subject to change in light of future developments. Except as required by law, the Company shall not be obligated to update or publicly revise any forward-looking statements or unforeseen events after the date of such statements, whether as a result of new information, future events or other circumstances. Please read this document carefully and understand that actual future performance or results of the Company may differ materially from expectations due to various risks, uncertainties or other statutory requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment. In February 2026, dorzagliatin (Trade name: MYHOMSIS®,) was approved for marketing by the Pharmaceutical Services of the Department of Health of the Government of the Hong Kong Special Administrative Region of China.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsEmail: ir@huamedicine.comMediaEmail: pr@huamedicine.com Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com

- 华堂宁(R)全年銷量超400萬盒，同比增長91%，銷售額達4.929億元，同比增長93%，公司全面自主商業化運營成效卓著。- 實現創紀錄盈利，稅前盈利達11.064億元；現金餘額穩健，截至年末達 10.923億元，為持續運營發展奠定堅實基礎。- 毛利率提升至56.9%，銷售開支占比從59.9%優化至33.6%，盈利能力顯著增強。- 华堂宁(R)原價續約新版醫保目錄，2026-2027年維持2025年的價格不變，臨床價值和創新價值再獲認可。- 隨著PTE獲批，中國市場獨佔權獲5年延期至2034年4月，商業確定性進一步提升。- 多格列艾汀（HYHOMSIS(R) ，華領片(R)）獲得香港地區上市批准，加速其面向東南亞的全球擴張進程。- 發佈多項真實世界證據，證實多格列艾汀治療優勢。- 持續拓展血糖穩態治療潛力，啟動多項全新的疾病首創新適應症研究，研究範圍涵蓋糖尿病預防、罕見病、輕度認知障礙及衰弱症領域。上海, 2026年3月27日 - (亞太商訊) - 華領醫藥（「公司」，香港聯交所股份代號：2552）宣佈公司及其附屬公司截至2025年12月31日止年度（「報告期」）經審核的綜合業績。報告期內，公司核心產品、全球首創抗糖尿病新藥、葡萄糖激酶激活劑（GKA）华堂宁(R)（多格列艾汀片）實現全方位推進，公司自主商業化團隊於運營首年即實現高效組建和運轉，研發管線持續豐富，財務表現實現歷史性突破，成功邁入盈利新階段，為全球糖尿病治療領域的創新發展注入強勁動力。華領醫藥創始人、CEO陳力博士表示：「2025年是華領醫藥商業化運營中的意義非凡的一年。公司成功完成從研發驅動型組織向商業化驅動型組織的轉型，具備了全球首創新藥、血糖穩態調節劑华堂宁(R)的完全自主商業化運營能力。憑藉強勁的市場執行力與產品競爭力，相較於2024年將商業化業務委託給營銷合作夥伴的階段，公司的銷量與營收實現了近三位數的增長。與此同時，通過推動多格列艾汀在香港的註冊工作，公司在全球市場拓展方面取得了關鍵性進展，我們將向覆蓋7億人口的東南亞地區進行市場佈局。我們持續拓展血糖穩態調控技術的臨床應用場景，積極佈局早期阿爾茨海默病、衰弱症等新適應症領域。針對GCK-MODY及衰弱症開展的疾病首創新藥研發工作，將為華領醫藥未來五年的創新發展劃定全新方向。」業務亮點與運營進展- 商業化全面發力，盈利實現歷史性突破2025年1月1日起，公司正式全面接管华堂宁(R)在中國的商業化工作，獲得全部運營與戰略主導權，公司成功搭建了專業的銷售團隊，覆蓋全國10個銷售區域，專注於產品營銷、醫學事務及商業運營。通過人工智能賦能的數字商業化平台，運營效率與銷售生產力大幅提升，為公司商業化發展注入新活力。受益於國家醫保藥品目錄的持續廣泛覆蓋，华堂宁(R)在二級和三級醫院的處方量顯著增長，患者可及性不斷提高，通過3000多家醫院、社區衛生中心、藥房和線上渠道，惠及超過50萬名患者。報告期內，產品銷量達401.1萬盒，同比增長91%；銷售額達4.929 億元，同比增長93%，在單價保持穩定的情況下，充分印證了市場需求的強勁增長和自主商業化團隊的高效執行能力。盈利能力方面，2025年，公司毛利達到2.804億元，同比增長125%，得益於生產規模擴大及製造工藝優化，公司毛利率從2024年的48.7% 提升至56.9%，增加8.2個百分點；銷售開支僅增長1230萬元至1.655億元，占收入比例優化至33.6%，較2024年的59.9%大幅下降；商業化業務實現約1.149億元盈利（按毛利扣除銷售開支計算）。公司預期仍將持續擴充商業化團隊規模，但商業化運營的盈利趨勢也將持續增長。在2024年底終止與拜耳合作後，多格列艾汀銷售額創歷史新高，報告期內，公司稅前盈利增加至人民幣11.064億。截至2025年末，現金結餘約為人民幣10.923億元，穩健的現金情況為公司持續發展奠定了堅實基礎。- 全球佈局加速推進，核心權益得到強化公司全球化佈局邁出關鍵步伐。2026年2月27日，多格列艾汀（香港地區商品名：MYHOMSIS(R)，華領片(R)）成功獲得香港監管機構的上市批准，公司計劃2026年中正式在香港市場推出該產品，並將進一步向亞洲地區拓展。此外，公司已于2025年向澳門藥監局遞交華領片(R)（MYHOMSIS(R)）的新藥上市申請。公司在知識產權保護方面也再獲進展。2026年2月，中國國家知識產權局批准多格列艾汀專利期限補償（PTE）申請，核心專利保護期延長至2034年4月，新增5年市場獨佔權，為產品長期市場競爭提供有力保障。2025年，多格列艾汀獲中國監管機構認定為國家級創新藥及慢病有效治療藥物，國家醫保局已確認，2026-2027年，华堂宁(R)的國家醫保目錄價格維持不變，公司將持續保障產品的市場競爭力和患者可及性，尤其在二級和三級醫院，加速患者的用藥普及。- 真實世界研究推進，臨床價值獲持續驗證真實世界證據（RWE）研究持續佐證多格列艾汀在葡萄糖依賴性胰島分泌功能改善中的關鍵作用，並顯示其在糖尿病預防、緩解及延緩或預防糖尿病併發症方面的功效。HMM0701已完成入組，共招募380名2型糖尿病患者。2025年6月，在美國ADA年會上發表的中期分析結果顯示，86%的患者同時服用兩種或以上降血糖藥物，41%的患者使用胰島素。經6個月治療後，血糖控制明顯改善，糖化血紅蛋白由8.1%降至7.3%，平均TIR（目標範圍內時間）提升至70%以上。迄今為止的研究顯示，多格列艾汀與其他降糖藥物聯合使用時，患者的餐後血糖水平和β細胞功能均顯著改善。另外，在美國進行的多格列艾汀機制研究（採用雙示蹤劑測量法），為平均確診糖尿病17年的2型糖尿病患者的肝糖原生成提供了科學證據。在該研究中，患者每日服用兩次多格列艾汀，持續6周。結果顯示，多格列艾汀能增加葡萄糖直接流入肝糖原的通量，意味著其有助於恢復肝臟GK功能。結合臨床研究數據顯示，多格列艾汀可改善早期胰島素釋放和GLP-1分泌，恢復2型糖尿病患者的肝臟GK功能，不僅為控制餐後血糖波動提供重要途徑，並在控制糖尿病併發症（如糖尿病腎病變及輕度認知障礙）方面提供獨特契機。HMM0601研究已經完成臨床試驗，共納入2000名受試者，平均患病時間為7.9年，其中超過30%患病時間超過10年。初步結果顯示，多格列艾汀在中國2型糖尿病患者中安全性、耐受性良好。研究中未觀察到新的不良反應，不良反應發生率維持在III期臨床試驗中觀察到的低水平，患者的用藥依從性普遍較高，平均依從率約為95%。在本研究中，80%的受試者已使用一種或多種口服降血糖藥，20%的受試者使用胰島素。多格列艾汀不僅在整體患者群體中展現出良好的療效及安全性，在老年、肥胖及高血糖患者群體中同樣有效，無論作為單藥治療或與二甲雙胍、SGLT-2抑制劑、胰島素及其他藥物聯合使用。頂線結果將於2026年ADA年會上發表。- 臨床研發持續深化，新適應症不斷拓展多格列艾汀用於治療MODY-2患者。中國內地及香港地區醫學專家已獨立開展多格列艾汀用於MODY-2治療的臨床研究及臨床前研究。MODY-2（又稱GCK-MODY）是一種單基因疾病，患者因葡萄糖激酶基因(GCK)存在遺傳缺陷，導致血糖升高及第二時相胰島素釋放顯著減少。在中國，MODY-2患者群體規模約為170萬人。此類患者確診糖尿病時年齡偏小，且由於現有治療藥物療效不佳，這一患者群體存在未被滿足的醫療需求。中國研究人員在針對MODY-2患者的臨床研究中報告指出，對於先前使用二甲雙胍、TZD、DPP-4抑制劑及SGLT-2抑制劑仍無法控制高血糖的MODY-2患者，多格列艾汀能有效將血糖降至正常水平。其他結果顯示，單劑量多格列艾汀可顯著改善這類患者的整體葡萄糖敏感性及第二時相胰島素分泌，表明多格列艾汀具有調節GLP-1分泌的獨特作用機制。基於以上結果，華領醫藥已與國家藥品監督管理局（NMPA）藥品審評中心溝通，將於2026年提交多格列艾汀用於MODY-2患者的IND申請。多格列艾汀用於糖尿病預防。糖尿病預防是華領醫藥的重要研發重點。公司已於香港啟動針對糖尿病前期糖耐量異常（IGT）受試者及早期糖尿病患者的SENSITIZE 3臨床研究。這項雙盲安慰劑對照研究將評估受試者在靜脈葡萄糖耐量試驗及口服葡萄糖耐量試驗下的血糖控制及胰島功能，以更明確界定臨床治療基線及終點指標。我們預計於2026年完成研究後，將在中國及亞太地區探索提交多格列艾汀用於糖尿病預防的IND申請的新機遇。多格列艾汀用於神經退行性疾病。研究顯示，中國老年人的輕度認知障礙患病率約為15.5%，美國則約為22%；該症狀在2型糖尿病患者中也相當常見，發病率達45%。多格列艾汀用於神經退行性疾病的研究已成為公司藥物研發工作的新焦點。通過全基因組關聯分析(GWAS)及孟德爾隨機化（MR）研究，我們發現GK基因激活在預防人類記憶力衰退及認知障礙方面具有重要作用。同時我們也發現，餐後血糖波動與阿茲海默症及失智症密切相關。血糖穩態異常及糖尿病狀況會導致大腦葡萄糖轉運蛋白及胰島素受體表達減少，而低劑量多格列艾汀可預防該功能損傷。我們已確認多格列艾汀在治療輕度認知障礙方面的潛在價值，並將於未來啟動針對該疾病領域的首創療法的相關臨床研究。多格列艾汀用於治療衰弱症。衰弱症是一種與年齡相關的老年綜合症，其特徵為對內外應激因子的耐受性降低。約17%的美國人及11%的亞洲人（50歲以上）患有衰弱症，而處於衰弱症前期者則分別約占此兩個群組的50%及47%。衰弱症並非單一器官疾病，而是多系統內穩態失調所導致的後果。遺傳學證據支持GK激活對降低衰弱症風險具有因果作用。我們計劃於未來啟動臨床研究，以推進多格列艾汀在衰弱症治療領域的應用。聯合用藥用於糖尿病及併發症的治療。臨床與基礎研究結果顯示，多格列艾汀能恢復胰腺在葡萄糖刺激下的胰島素及GLP-1分泌，也可以通過恢復2型糖尿病患者肝臟葡萄糖激酶功能，改善肝臟胰島素敏感性並降低肝臟胰島素抵抗。多格列艾汀與DPP-4抑制劑、SGLT-2抑制劑及GLP-1受體激動劑的聯合使用已證明可有效調節脂質代謝，與抗癌PI3K抑制劑聯合使用的研究也為血糖穩態管理帶來獨特優勢。- 產品管線豐富多元，創新佈局未來增長華領醫藥在核心產品基礎上持續豐富管線佈局。依託多格列艾汀與二甲雙胍聯合用藥在III期臨床試驗和真實世界應用中取得的優異數據，公司加速推進多格列艾汀與二甲雙胍固定複方製劑（FDC）的研發。該製劑為每日兩次給藥方案，適用于單用二甲雙胍血糖控制不佳的2型糖尿病患者，旨在以進一步提升患者的用藥依從性。公司已向NMPA提交IND申請文件。此外，GMP商業化生產工藝也已成功開展，為2027年新藥上市申請的關鍵生物等效性研究做好準備。臨床研究顯示，多格列艾汀與二甲雙胍聯用能夠更好地控制血糖，降低餐後血糖，改善空腹血糖，為優化血糖穩態終點提供了新的臨床價值。第二代GKA的研發取得重要突破。作為肥胖2型糖尿病患者每日一次治療的緩釋新片劑，公司已在美國啟動多格列艾汀多劑量遞增（MAD）研究，以探討第二代GKA在血糖穩態控制方面的療效及新藥的作用機制，首例患者已於2025年12月入組，預計2026年中公佈頂線數據。同時，公司還在探索多格列艾汀與GLP-1受體激動劑、SGLT-2抑制劑等藥物的聯合治療方案。近期，在一項中國的臨床試驗中，研究者報告：多格列艾汀聯合司美格魯肽治療12周，療效顯著優於司美格魯肽單藥治療。聯合治療組在血糖控制、體重相關指標及β細胞功能等多項關鍵指標上均表現更優。財務摘要截至2025年12月31日，- 华堂宁(R)全年銷量約401.1萬盒，相較2024年全年，同比增長91%，實現營收約4.929億元，同比增長93%。- 毛利約人民幣2.804億元，同比增長125%，毛利率提升至56.9%；- 稅前盈利約人民幣11.064億元，較2024年增長542%；- 銀行結餘及現金約人民幣10.923億元，資金狀況穩健；- 總開支約人民幣4.334億。前瞻性聲明本文包含有關華領醫藥以及產品未來預期、計劃和前景的陳述。該等前瞻性陳述僅與本文作出該陳述當日的事件或資料有關，可能因未來發展而出現變動。除法律規定外，於作出前瞻性陳述當日之後，無論是否出現新資料、未來事件或其他情況，我們並無責任更新或公開修改任何前瞻性陳述及預料之外的事件。請仔細閱讀本文並理解，由於各種風險、不確定性或其他法定要求我們的實際未來業績或表現可能與預期有重大差異。關於華領華領醫藥（「本公司」）是一家總部位於中國上海的創新藥物研發和商業化公司，在美國、中國香港設立了公司。華領醫藥專注於未被滿足的醫療需求，為全球患者開發全新療法。華領醫藥彙聚全球醫藥行業高素質人才，融合全球創新技術，依託全球優勢資源，研究開發突破性的技術和產品，引領全球糖尿病醫療創新。公司核心產品华堂宁(R)（多格列艾汀片）以葡萄糖傳感器葡萄糖激酶為靶點，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖穩態失調。2022年9月30日，华堂宁(R)已獲得中國國家藥品監督管理局（NMPA）的上市批准，用於單獨用藥或者與二甲雙胍聯合用藥，治療成人2型糖尿病。對於腎功能不全患者，無需調整劑量，是一款可用於腎功能損傷的2型糖尿病患者的口服降糖藥物。2026年2月，多格列艾汀（商品名：MYHOMSIS(R)，華領片(R)）獲得中國香港特別行政區政府衛生署藥物辦公室的上市批准。詳情垂詢華領醫藥網址：www.huamedicine.com投資者電郵：ir@huamedicine.com媒體電郵：pr@huamedicine.com新聞免責聲明本材料，如為上下文論述的準確性和完整性，提及在中國上市的產品相關信息的，特別是標識或要求，應遵循中國監管機構批准的相關文件。另外，相關信息不應被解讀為對任何藥物或者診療方案的推薦或者宣傳，亦不應替代任何醫療衛生專業人士的醫療建議，涉及醫療的相關事宜務必諮詢醫療衛生專業人士。 Copyright 2026 亞太商訊. All rights reserved. www.acnnewswire.com

香港, 2026年3月27日 - (亞太商訊) - 3月26日，雲知聲（09678.HK）發佈截至2025年12月31日止年度的經審核全年業績，展現上市後首份成績單強勁的增長動能與持續優化的財務結構。營收結構持續優化，下半年增長提速2025年全年，雲知聲實現總營收12.1億元人民幣，同比增長29%。其中，下半年收入同比增長33%，達8.1億元。值得關注的是，公司大模型業務全年收入6.1億元，同比增長超10倍。尤其是下半年，該業務貢獻收入約5億元，為上半年規模的5倍，顯示出強勁的規模化落地能力。虧損大幅收窄，盈利路徑日漸清晰在營收高速增長的同時，公司虧損狀況顯著改善。2025年下半年，公司淨虧損同比收窄84%，經調整後虧損同比收窄92%，接近盈虧平衡點，反映出公司在成本控制與運營效率方面的持續優化。同時，公司的部分經營指標也得到明顯改善。經調整營業費用率較去年同比大幅下降10%，銷售費用不升反降，佔收入比重僅為5.4%，費效比提升明顯。從數據端來看，2025年公司人均產值為252萬元/人，相較24年的202萬元同比增長25%，人均創效能力持續領跑行業，直觀彰顯了公司技術驅動、精益運營的核心優勢。雙輪驅動戰略落地，智慧醫療與智慧生活齊頭並進2025年，在技術突破與政策紅利的雙重驅動下，全球人工智能市場需求持續升溫。雲知聲堅持「強基模+深應用」戰略，持續夯實全模态技術底座，推動自研大模型矩陣在醫療、語音、OCR等領域的全球影響力不斷提升。在商業化層面，公司以AI原生組織推動業務落地，智慧醫療與智慧生活雙輪驅動戰略成效顯著。報告期內：智慧生活業務實現收入9.68億元，同比增長30.8%。其中，智慧交通業務同比增長近40%，目前，已在青島、寧波、深圳、南寧等10餘個城市落地基於山海大模型的智能體應用。此外，AI芯片累計出貨量突破1.1億顆，進一步驗證公司在終端AI產品的規模化能力。智慧醫療業務實現收入2.44億元，同比增長22.3%，客單價同比增長53.2%。2025年，合作的醫院中超70%為三級醫院，且超過三分之一客戶已經連續合作三年以上；而基於醫療大模型的病歷錄入與生成產品已在某頭部三甲醫院單院區實現全年病歷生成同比增長10倍；商業保險智能體平台案件處理量同比增長37倍；與頭部保險集團的深度合作中，控費率水平有效提升至約20%，相較傳統審核方式實現超10億元級別的增量成本管控，全面賦能保險機構在醫療風控領域的精細化運營。持續加碼研發，夯實技術護城河為鞏固行業領先地位，2025年公司持續在技術端大力投入，全年研發費用超3.8億元，佔經調整三費的75%；研發人員佔比達69%。持續的研發投入在多個技術領域取得突破，如在MedBench 4.0評測中，公司一舉斬獲「醫療智能體」「醫療大語言模型」「醫療多模态大模型」三項技術範式第一，榮膺「三冠王」。未來展望：深耕技術底座，拓展應用邊界展望未來，雲知聲將繼續深化「強基模+深應用」戰略。技術層面，公司將持續加大對基座大模型的戰略性投入，力爭保持全球一流水平；應用層面，將以MaaS（模型即服務）與智能體的規模化拓展為核心增長引擎，推動智慧生活與智慧醫療業務的指數級增長。同時，公司正積極探索以API調用、Token計費等模式構建經常性收入體系，並將C端產品機會作為第二增長曲線，進一步拓展商業化邊界。2026年第二季度，雲知聲將推出面向編程和辦公的原生智能體大模型，並預計能實現智能密度和Token生產效率的倍增。 Copyright 2026 亞太商訊. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 27, 2026 - (ACN Newswire) – 26 March, Unisound (09678.HK) announced its audited annual results for the year ended December 31, 2025. As the Company's first annual results announcement since listing, it underscores strong growth momentum and continued improvement in its financial profile.Revenue Mix Continues to Improve, with Faster Growth in H2For the full year of 2025, Unisound achieved total revenue of $175 million, representing a year-on-year (YoY) increase of 29%. Revenue in the second half of the year increased by 33% YoY to $117 million.It is worth noting that the Company's large language model (LLM) business generated a full-year revenue of $88.43 million, surging by over 10 times YoY. In particular, this business contributed approximately $72.49 million in H2 revenue, five times the level recorded in H1, demonstrating a compelling capacity for large-scale commercial application.Losses Narrowed Significantly, Making the Path to Profitability Increasingly ClearAlongside the rapid revenue growth, the Company's losses improved markedly. In the second half of 2025, the Company's net loss narrowed by 84% YoY, and its adjusted loss narrowed by 92% YoY, approaching break-even. This reflects the Company's ongoing improvements in cost control and operational efficiency.Simultaneously, some of the Company's operating metrics saw marked improvement. The adjusted expense ratio declined significantly by 10 percentage points YoY, while selling expenses decreased rather than increased and accounted for only 5.4%, highlighting a clear improvement in cost-to-efficiency ratio. In 2025, revenue per employee reached $365,300, up 25% YoY from $292,900 in 2024. Employee productivity continued to lead the industry, clearly underscoring the Company's core strengths in technology-driven, lean operations.Dual-Engine Strategy Gains Traction, with AI in Healthcare and AI in Daily Life Advancing in TandemIn 2025, driven by both technological breakthroughs and policy tailwinds, global demand for AI continued to rise. Unisound adhered to its "Strong Foundation Model + Deep Application" strategy, continued to strengthen its multimodal technology foundation, and drove the continuous elevation of the global influence of its proprietary large model matrix in fields such as healthcare, speech, and OCR.On the commercialization front, the Company leveraged its AI-native organization to accelerate business execution, and its dual-engine strategy in AI in Healthcare and AI in Daily Life delivered notable results. During the reporting period:The AI in Daily Life business achieved revenue of $140 million, a YoY increase of 30.8%. Among this, the Transportation segment recorded nearly 40% YoY growth. At present, AI agent applications based on the Shanhai large model have been deployed in more than 10 cities, including Qingdao, Ningbo, Shenzhen and Nanning. In addition, cumulative AI chip shipments exceeded 110 million units, further validating the Company's scale capabilities in endpoint AI products.The AI in Healthcare business achieved revenue of $35.38 million, a YoY increase of 22.3%, with average revenue per customer growing by 53.2% YoY. In 2025, over 70% of the hospitals the Company collaborated with were tertiary hospitals, and more than one-third of customers had maintained continuous cooperation for over three years. The medical-record entry and generation products powered by the medical large model delivered a 10-fold YoY increase in full-annual medical record generation at a single campus of a leading Class III hospital. The commercial insurance AI agent platform recorded a 37-fold YoY increase in case processing volume. In deep cooperation with a leading insurance group, the expense control rate was effectively raised to approximately 20%, delivering more than $145 million in incremental cost management compared with traditional review methods, comprehensively empowering insurance institutions to refine their medical risk management operations.Continued R&D Investment Strengthens the Technology MoatTo consolidate its industry-leading position, the Company continued to invest heavily in R&D in 2025. Full-year R&D expenses exceeded $55.09 million, accounting for 75% of the Company's adjusted operating expenses, while R&D personnel accounted for 69% of the total workforce. This sustained investment drove breakthroughs across multiple technology areas. For example, in the MedBench 4.0 evaluation, the Company ranked first place in three technical paradigms: "Medical AI Agent," "Medical Large Language Model," and "Medical Multimodal Large Model," earning a "Triple Crown."Outlook: Deepening the Technological Foundation and Expanding Application BoundariesLooking ahead, Unisound will continue to deepen its "Strong Foundation Model + Deep Application" strategy. On the technological front, the Company will continue to increase strategic investment in foundational large models and strive to maintain a world-class level. On the application front, it will use the large-scale expansion of MaaS (Model-as-a-Service) and AI agents as its core growth engine, driving exponential growth in its AI in Daily Life and AI in Healthcare businesses. Meanwhile, the Company is actively exploring the establishment of a recurring revenue system through models such as API calls and Token-based billing, and regards opportunities in consumer-facing (C-end) products as a second growth curve to further expand its commercialization boundaries.Between Q2 and Q3 2026, Unisound will launch a native AI agent large model for programming and office applications, which is expected to double both intelligence density and token production efficiency. Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com